Infectious Diarrhea – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Infectious Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions.
Infectious Diarrhea is a common gastrointestinal infection and the most common type of diarrhea. Diarrhea is defined as frequent bowel movements that are loose, watery, and associated with nausea, vomiting, and fatigue. Bacterial, viral, and protozoans are the common pathogens leading to infectious diarrhea. E. coli-associated infections are the most common bacteria while Entamoeba histolytica is a common parasite causing infectious diarrhea. The mode of infection can be through contaminated food, water, medications, and diseases like IBD. As there a several losses of body fluids or secretion oral rehydrating therapy is the primary treatment option to treat dehydration. Stool examination to analyze the pathogens, complete blood tests, and serum electrolytes are diagnostic methods. Abdominal pain, frequent bowel movements, nausea, and vomiting are common symptoms. Antibiotics, anti-diarrheal, and anti-emetics are common medications used.
The Infectious Diarrhea drugs in development market research report provide comprehensive information on the therapeutics under development for Infectious Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Infectious Diarrhea and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Infectious Diarrhea | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Infectious Diarrhea therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Infectious Diarrhea pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Infectious Diarrhea treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Brillian Pharma Inc.Glycosyn LLC
Hilleman Laboratories Pvt Ltd
Immuron Ltd
Jaguar Health Inc
Johns Hopkins University
Napo Pharmaceuticals Inc
Nuvara Therapeutics LLC
Theriva Biologics Inc
University of Tennessee Research Foundation
US Army Medical Research & Materiel Command
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Infectious Diarrhea reports